A randomized,double-blind, active controlled,15 week study to evaluate the effects of nebivolol and valsartan alone and in combination on 24-hour ambulatory cardiac work and variability of heart rate-mean central systolic pressure product.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Subjects with chronic hypertension, treated or untreated
* Males and females, 18 years or older
* Seated clinic systolic BP 145-184 mmHg inclusive or
* Seated clinic diastolic BP 92-119 mmHg, inclusive.
Exclusion Criteria:
* Subjects with any of the following conditions will be excluded:
* Any acute or chronic medical condition that, in the judgment of the investigator, renders the subject unable to complete the study, would interfere with optimal participation in the study, or cause significant risk to the subject
* Concomitant or probable need for treatment with other cardiovascular or antihypertensive drugs that may affect blood pressure or influence the effects of study drugs, (e.g. NSAIDs, beta-agonist inhalers therapy for bronchospastic asthma, diuretics); other stable chronic medications that have little effect on study drugs (e.g. diabetes medications, hormone replacements, chronic pain medications. osteoporosis drugs, vitamins, cholesterol drugs, etc.) are permitted if continued at stable doses throughout study.
* History of clinically significant adverse events with beta-blocker or angiotensin-receptor blocker
* Known or suspected secondary hypertension (e.g., renovascular hypertension, primary hyperaldosteronism, etc.)
* Known ischemic heart disease requiring continuous beta-blocker therapy (includes angina, prior transmural myocardial infarction, coronary artery bypass graft surgery or percutaneous transluminal coronary a…
What they're measuring
1
ACRPP: 24-hour Ambulatory Central Rate-pressure Product (Also Called TTI, CTTI)
Timeframe: measurement after 4 weeks in each treatment arm